scholarly journals Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience

2021 ◽  
Vol 144 ◽  
pp. 1-8
Author(s):  
P. Berlanga ◽  
C. Pasqualini ◽  
U. Pötschger ◽  
C. Sangüesa ◽  
M.R. Castellani ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
High Risk ◽  
Central Nervous System Relapse ◽  
Trial Experience ◽  
Stage 4

scholarly journals Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis

Blood ◽  
1979 ◽  
Vol 54 (6) ◽  
pp. 1249-1257 ◽  
Author(s):  
JP Litam ◽  
F Cabanillas ◽  
TL Smith ◽  
GP Bodey ◽  
EJ Freireich
Keyword(s):  
Risk Factors ◽  
Central Nervous System ◽  
Nervous System ◽  
High Risk ◽  
Malignant Lymphoma ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Central Nervous System Relapse ◽  
Cns Relapse

Abstract The records of 292 patients with malignant lymphoma other than Hodgkin's disease, registered in our protocols from 1967 to 1977, were reviewed to identify those with central nervous system (CNS) involvement. Thirty-one patients were encountered with this complication, an incidence of 11%. Patients with a diffuse histology had a higher frequency of CNS recurences (27/174 = 16%) in contrast to only 4/118 (3%) for those with nodular types. However, if only patients with diffuse histology in CR are considered, the frequency of CNS relapse is 13.5% (13/98). The risk factors that predict for the development of this complication were studied using multivariate analysis. Diffuse poorly differentiated lymphocytic and diffuse undifferentiated lymphomas were found to be associated with a high risk of CNS relapse. Prior chemotherapy, bone marrow involvement, age less than 35, and extranodal disease were also identified as high-risk factors. Using the information generated by a logistic regression model, patients with malignant lymphoma of diffuse type can be classified into three categories when first seen: low-risk group, intermediate, and high-risk group. CNS prophylaxis is recommended for the intermediate and high-risk group, while only close follow-up is advised for the low-risk group patients who have one adverse characteristic.

scholarly journals Isolated central nervous system relapses in patients with high-risk neuroblastoma. Clinical presentation and prognosis: experience of the Polish Pediatric Solid Tumors Study Group.

2021 ◽  
Author(s):  
Aleksandra Wieczorek ◽  
Joanna Stefanowicz ◽  
Marcin Hennig ◽  
Elzbieta Adamkiewicz-Drozynska ◽  
Marzena Stypinska ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
High Risk ◽  
Solid Tumors ◽  
Young Patients ◽  
Clinical Problem ◽  
Brain Parenchyma ◽  
Study Group ◽  
Pediatric Solid Tumors ◽  
Stage 4

Abstract Although isolated central nervous system (CNS) relapses are rare, they may become a serious clinical problem in intensively treated patients with high-risk neuroblastoma (NBL). The aim of the study is presentation, assessment of incidence and the clinical course of isolated CNS relapses. Retrospective analysis involved 848 NBL patients treated from 2001 to 2019 at 8 centers of the Polish Pediatric Solid Tumors Study Group (PPSTSG). Group characteristics at diagnosis, treatment and patterns of relapse were analyzed. Observation was completed in December 2020. We analyzed 286 high risk patients, including 16 infants. Isolated CNS relapse, defined as presence of a tumor in brain parenchyma or leptomeningeal involvement, was found in 13 patients (4.5%, 8.4% of all relapses), all of them were stage 4 at diagnosis. Isolated CNS relapses seem to be more common in young patients with stage 4 MYCN amplified NBL, and in this group they may occur early during the first line therapy. The only or the first one symptom may be bleeding into CNS, especially in younger children, even without clear relapse picture on imaging, or the relapse may be clinically asymptomatic and found on routine screening. Although incidence of isolated CNS relapses is not statistically significantly higher in patients after immunotherapy, their occurrence should be carefully monitored, especially in intensively treated infants, with potential disruption of brain-blood barrier.

scholarly journals Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis

Blood ◽  
1979 ◽  
Vol 54 (6) ◽  
pp. 1249-1257 ◽  
Author(s):  
JP Litam ◽  
F Cabanillas ◽  
TL Smith ◽  
GP Bodey ◽  
EJ Freireich
Keyword(s):  
Risk Factors ◽  
Central Nervous System ◽  
Nervous System ◽  
High Risk ◽  
Malignant Lymphoma ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Central Nervous System Relapse ◽  
Cns Relapse

The records of 292 patients with malignant lymphoma other than Hodgkin's disease, registered in our protocols from 1967 to 1977, were reviewed to identify those with central nervous system (CNS) involvement. Thirty-one patients were encountered with this complication, an incidence of 11%. Patients with a diffuse histology had a higher frequency of CNS recurences (27/174 = 16%) in contrast to only 4/118 (3%) for those with nodular types. However, if only patients with diffuse histology in CR are considered, the frequency of CNS relapse is 13.5% (13/98). The risk factors that predict for the development of this complication were studied using multivariate analysis. Diffuse poorly differentiated lymphocytic and diffuse undifferentiated lymphomas were found to be associated with a high risk of CNS relapse. Prior chemotherapy, bone marrow involvement, age less than 35, and extranodal disease were also identified as high-risk factors. Using the information generated by a logistic regression model, patients with malignant lymphoma of diffuse type can be classified into three categories when first seen: low-risk group, intermediate, and high-risk group. CNS prophylaxis is recommended for the intermediate and high-risk group, while only close follow-up is advised for the low-risk group patients who have one adverse characteristic.

Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma

2010 ◽  
Vol 78 (3) ◽  
pp. 849-854 ◽  
Author(s):  
Victoria J. Croog ◽  
Kim Kramer ◽  
Nai-Kong V. Cheung ◽  
Brian H. Kushner ◽  
Shakeel Modak ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
High Risk ◽  
Central Nervous System Relapse

Early Detection of Central Nervous System Relapse of Pediatric Leukemia with Measurement of Optic Nerve Sheath Diameter on MRI

2019 ◽  
Vol 15 (2) ◽  
pp. 237-241
Author(s):  
Taner Arpaci ◽  
Barbaros S. Karagun
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Optic Nerve ◽  
Early Detection ◽  
Optic Nerve Sheath Diameter ◽  
Central Nervous System Relapse ◽  
Mri Findings ◽  
Pediatric Leukemia ◽  
Optic Nerves ◽  
Cns Relapse

Background: Leukemia is the most common pediatric malignancy. Central Nervous System (CNS) is the most frequently involved extramedullary location at diagnosis and at relapse. </P><P> Objective: To determine if Magnetic Resonance Imaging (MRI) findings of optic nerves should contribute to early detection of CNS relapse in pediatric leukemia. Methods: Twenty patients (10 boys, 10 girls; mean age 8,3 years, range 4-16 years) with proven CNS relapse of leukemia followed up between 2009 and 2017 in our institution were included. Orbital MRI exams performed before and during CNS relapse were reviewed retrospectively. Forty optic nerves with Optic Nerve Sheaths (ONS) and Optic Nerve Heads (ONH) were evaluated on fat-suppressed T2-weighted TSE axial MR images. ONS diameter was measured from the point 10 mm posterior to the globe. ONS distension and ONH configuration were graded as 0, 1 and 2. Results: Before CNS relapse, right mean ONS diameter was 4.52 mm and left was 4.61 mm which were 5.68 mm and 5.66 mm respectively during CNS relapse showing a mean increase of 25% on right and 22% on left. During CNS relapse, ONS showed grade 0 distension in 15%, grade 1 in 60%, grade 2 in 25% and ONH demonstrated grade 0 configuration in 70%, grade 1 in 25% and grade 2 in 5% of the patients. Conclusion: MRI findings of optic nerves may contribute to diagnose CNS relapse by demonstrating elevated intracranial pressure in children with leukemia.

Central nervous system relapse in acute promyelocytic leukemia

2002 ◽  
Vol 71 (1) ◽  
pp. 60-61 ◽  
Author(s):  
N. Colovic ◽  
A. Bogdanovic ◽  
P. Miljic ◽  
G. Jankovic ◽  
M. Colovic
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Central Nervous System Relapse
Sign in / Sign up

Export Citation Format

Share Document